Check for updates

OPEN ACCESS

EDITED BY Zhifang Zhang, City of Hope National Medical Center, United States

REVIEWED BY

Osvaldo Mazza, Bambino Gesù Children's Hospital (IRCCS), Italy Achille Aveta, University of Naples Federico II, Italy

*CORRESPONDENCE Cihangir Türemiş 🖂 cihangirturemis@gmail.com

RECEIVED 21 September 2023 ACCEPTED 11 December 2024 PUBLISHED 08 January 2025

CITATION

Türemiş C, Çeltik M and Erduran M (2025) Case Report: Metastatic involvement of the acromioclavicular joint in a patient with papillary carcinoma of the ureter. Front. Surg. 11:1298556. doi: 10.3389/fsurg.2024.1298556

COPYRIGHT

© 2025 Türemiş, Çeltik and Erduran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Case Report: Metastatic involvement of the acromioclavicular joint in a patient with papillary carcinoma of the ureter

Cihangir Türemiş^{1*}, Mustafa Çeltik² and Mehmet Erduran³

¹Cesme Alper Cizgenakat State Hospital, Izmir, Türkiye, ²Kağızman State Hospital, Kars, Türkiye, ³Department of Orthopedics, Dokuz Eylul University, Izmir, Türkiye

Ureteral papillary carcinoma is a rare subtype of urothelial carcinoma, ranking fourth among cancers following prostate (or breast) cancer, lung cancer, and colorectal cancer. Although previous studies have documented bone metastases mainly in the pelvis, spine, ribs, and femur, this case report presents the first recorded instance of metastasis occurring in the acromioclavicular joint. A 62-year-old woman with a history of left flank pain and macroscopic hematuria underwent a left nephroureterectomy, which revealed ureteral papillary carcinoma. Three years later, she reported left shoulder pain, leading to the discovery of a metastatic lesion in the distal clavicle. Approximately 9 cm of metastatic bone was resected while preserving nearby nerve and vascular structures. The resulting bone defect was grafted with a 9-cm bone graft removed from the middle third of the fibula. This case report underscores the importance of considering distant metastases, even in atypical locations, in patients with ureteral papillary carcinoma and aims to share the entire treatment journey and insights gained.

KEYWORDS

ureteral papillary carcinoma, acromioclavicular (AC) joint, metastases, clavicula, reconstruction method

Introduction

Ureteral papillary carcinoma is a rare form of urothelial carcinoma, ranking fourth among malignancies after prostate (or breast) cancer, lung cancer, and colorectal cancer (1). Upper tract urothelial carcinoma (UTUC) comprises 5%–10% of urothelial cancers, with bladder cancer (BC) being the most common (2). UTUCs peak in those aged 70–90 years and are three times more common in men (3). While most cases remain localized, the metastatic spread can impact multiple organs, mainly via hematogenous and lymphatic pathways, ultimately affecting survival rates (4–6). Bone metastases have been reported in the literature, primarily involving the pelvis, spine, ribs, and femur (7, 8). There are no reported cases of acromioclavicular (AC) involvement in papillary carcinoma of the ureter in the literature, emphasizing the rarity of such metastatic involvement. This case report further broadens the understanding of the course of the disease by showing that the clavicle, acromioclavicular joint, and surrounding tissues may also be involved.





(Top) Images of an intraoperatively removed mass and fixation of a fibular graft endobutton. (Bottom) Perioperative direct radiograph and CT 3D.

Case presentation

FIGURE 2

A 62-year-old woman presented to the urology outpatient clinic with a 6-month history of left flank pain and intermittent macroscopic hematuria. The ultrasound examination revealed significant hydronephrosis along with enlarged renal parenchyma. A computed tomography (CT) scan of the abdomen showed a lesion in the ureter accompanied by proximal dilatation, hydronephrosis, and a dysfunctional ipsilateral renal unit. Retrograde urography revealed several filling defects along with a 2.5-cm lesion featuring a smooth contour, prompting a biopsy. A left nephroureterectomy was performed, and the pathology result was diagnosed as ureteral papillary carcinoma.

During her postoperative follow-up, 3 years after surgery, the patient reported pain in her left shoulder. Subsequently, an x-ray examination was performed to assess for potential masses, which revealed a heterogeneous solid lesion, measuring up to 6 cm, located at the distal end of the clavicle. The mass was evaluated via magnetic resonance imaging (MRI) and CT scans. The ensuing radiology report indicated the following: "Expansile mass lesion presumed to be metastatic, located in the distal part of the clavicle, accompanied by soft tissue and muscle edema (Figure 1)." The Musculoskeletal Tumor Council assessed the patient and opted for a biopsy. The true-cut biopsy results suggested possible metastases, prompting the need for surgery.

Surgical management

After anesthesia preparations, the patient was placed in the supine position. The ipsilateral left leg and left shoulder were prepped and sterile draped. An incision was then made over the left clavicle, allowing for the resection of approximately 9 cm of metastatic bone, while preserving the nerve and vascular structures. The bone defect was subsequently grafted using a 9-cm long bone graft removed from the middle third of the fibula. The removed fibular bone graft was fixed to the medial clavicle with a dynamic compression plate. The distal part of the

bone graft was stabilized from the graft to the coracoid using the endobutton method and from the graft to the acromion using a hook plate to ensure both horizontal and vertical stability of the acromioclavicular joint (Figure 2). The patient began isometric shoulder exercises in the second week after the wound site follow-up with a shoulder sling. The material sent to pathology was diagnosed as metastatic ureteral papillary carcinoma. She was referred to the Oncology Department.

Discussion

This case report highlights the importance of considering distant metastases, even in unusual sites, in patients with ureteral papillary carcinoma. Metastatic recurrence of ureteral papillary carcinoma mainly occurs in the retroperitoneal, pelvic, and supraclavicular lymph nodes, indicating the lymphatic spread of cancer cells (9). The abundant blood supply and broad lymphatic network surrounding the AC joint may promote these metastases. At the same time, cytotoxic chemotherapy agents may damage the lymphatic and vascular structures around the joint, potentially leading to direct invasion. Clinicians may overlook rare metastases and subtle symptoms of patients related to other specialties if they evaluate them solely within their specialty. Therefore, a multidisciplinary approach is necessary assess diseases involving metastases. Comprehensive to multidisciplinary follow-up, examinations, and treatment are vital to prevent early recurrence and further metastasis.

This unusual presentation of metastatic ureteral papillary carcinoma emphasizes the necessity for a comprehensive multidisciplinary evaluation of the patient when metastases are suspected. It also highlights the mechanisms of potential metastasis and their implications for clinical practice and future research.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.

References

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. *Pharmacoeconomics.* (2003) 21:1315–30. doi: 10.1007/BF03262330

2. Pandolfo SD, Cilio S, Aveta A, Wu Z, Cerrato C, Napolitano L, et al. Upper tract urothelial cancer: guideline of guidelines. *Cancers (Basel)*. (2024) 16(6):1115. doi: 10. 3390/cancers16061115

3. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. *Eur Urol.* (2021) 79(1):62–79. doi: 10.1016/j.eururo.2020.05.042

4. Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. *World J Urol.* (2013) 31:141–5. doi: 10. 1007/s00345-012-0877-2

5. Bianconi M, Cimadamore A, Faloppi L, Scartozzi M, Santoni M, Lopez-Beltran A, et al. Contemporary best practice in the management of urothelial carcinomas of the

Ethics statement

The studies involving humans were approved by the Dokuz Eylul University Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

CT: Conceptualization, Investigation, Methodology, Project administration, Writing – original draft. MÇ: Resources, Validation, Writing – review & editing. ME: Project administration, Software, Supervision, Visualization, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

renal pelvis and ureter. Ther Adv Urol. (2019) 11:1756287218815372. doi: 10.1177/1756287218815372

6. Nelson AA, Cronk RJ, Lemke EA, Szabo A, Khaki AR, Diamantopoulos LN, et al. Early bone metastases are associated with worse outcomes in metastatic urothelial carcinoma. *Bladder Cancer.* (2021) 7:33-42. doi: 10.3233/ BLC-200377

7. Tsuda Y, Nakagawa T, Shinoda Y, Kanatani A, Kawai T, Taguchi S, et al. Skeletalrelated events and prognosis in urothelial cancer patients with bone metastasis. *Int J Clin Oncol.* (2017) 22(3):548–53. doi: 10.1007/s10147-016-1075-9

8. Guzman SJ, Kleinschmidt-DeMasters BK. Urothelial carcinoma metastases impacting the CNS: a 20-year retrospective series. *Ann Diagn Pathol.* (2023) 64:152109. doi: 10.1016/j.anndiagpath.2023.152109

9. Kolawa A, D'Souza A, Tulpule V. Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. *Cancers (Basel).* (2023) 15(19):4813. doi: 10.3390/cancers15194813